Current Assets
Finished goods
Regeneron Pharmaceuticals Finished goods decreased by 15.6% to $160.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 45.9%, from $110.00M to $160.50M. Over 5 years (FY 2020 to FY 2025), Finished goods shows an upward trend with a 9.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
A decrease relative to sales may indicate strong demand, while an increase may signal slowing sales or inventory accumulation.
Detailed definition
This represents the value of completed products ready for sale to customers, net of any reserves for obsolescence or slo...
Peer comparison
Standard inventory metric for all manufacturing and industrial companies.
Metric ID:
current_assets_inventory_finished_goods_net_of_reservesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $106.30M | $60.10M | $73.70M | $47.30M | $45.60M | $65.00M | $98.60M | $169.30M | $125.30M | $114.20M | $147.30M | $180.50M | $154.40M | $164.60M | $139.80M | $110.00M | $144.40M | $169.70M | $190.20M | $160.50M |
| QoQ Change | — | -43.5% | +22.6% | -35.8% | -3.6% | +42.5% | +51.7% | +71.7% | -26.0% | -8.9% | +29.0% | +22.5% | -14.5% | +6.6% | -15.1% | -21.3% | +31.3% | +17.5% | +12.1% | -15.6% |
| YoY Change | — | — | — | — | -57.1% | +8.2% | +33.8% | +257.9% | +174.8% | +75.7% | +49.4% | +6.6% | +23.2% | +44.1% | -5.1% | -39.1% | -6.5% | +3.1% | +36.1% | +45.9% |
Range$45.60M – $190.20M
CAGR+9.1%
Avg YoY Growth+40.7%
Median YoY Growth+28.5%
Finished goods at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's finished goods?
- Regeneron Pharmaceuticals (REGN) reported finished goods of $160.50M in Q1 2026.
- How has Regeneron Pharmaceuticals's finished goods changed year-over-year?
- Regeneron Pharmaceuticals's finished goods increased by 45.9% year-over-year, from $110.00M to $160.50M.
- What is the long-term trend for Regeneron Pharmaceuticals's finished goods?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's finished goods has grown at a 9.3% compound annual growth rate (CAGR), from $121.70M to $190.20M.
- What does finished goods mean?
- The value of completed products ready for sale, after accounting for potential losses.